Glioblastoma presents significant challenges in neuro-oncology due to its aggressive nature, drug resistance, and restrictions imposed by the blood-brain barrier.
Ivermectin (IVM), known for its antiparasitic properties, has been highlighted as a promising treatment for tumors and an alternative therapy for glioma, although it exhibits low oral bioavailability.
Therefore, we investigated the
